Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · September 14, 2023

Outcomes of Neratinib + Fulvestrant + Trastuzumab and Biomarker Analysis in Patients With HR+/HER2−, HER2-Mutant MBC

Annals of Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Annals of Oncology
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial
Ann. Oncol 2023 Aug 17;[EPub Ahead of Print], K Jhaveri, LD Eli, H Wildiers, SA Hurvitz, A Guerrero-Zotano, N Unni, A Brufsky, H Park, J Waisman, ES Yang, I Spanggaard, S Reid, ME Burkard, S Vinayak, A Prat, M Arnedos, FC Bidard, S Loi, J Crown, M Bhave, SA Piha-Paul, JM Suga, S Chia, C Saura, JÁ Garcia-Saenz, V Gambardella, MJ de Miguel, EN Gal-Yam, A Rapael, SM Stemmer, C Ma, AB Hanker, D Ye, JW Goldman, R Bose, L Peterson, JSK Bell, A Frazier, D DiPrimeo, A Wong, CL Arteaga, DB Solit

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading